Finally, the data that we generated during the course of the study indicate that whilst direct Fas-FasL killing of the Treg may contribute to tumour rejection, the main contribution to tumour rejection is via depletion of Treg using the CD25-specific mAb PC61. This evidence concerns the gene FASLG and neoplasm.